Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL: Adalimumab and Methotrexate Strategies in PsA
NCT02814175Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2016
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 4, randomised, open-label trial of adalimumab in psoriatic arthritis (PsA) (6 arms), sponsored by AbbVie Inc. Primary endpoint: Minimal Disease Activity at 16 weeks. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02814175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814175.